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Abstract
Background: Toll-like receptors (TLR) are key innate immunity receptors participating in an immune response.
Growing evidence suggests that mutations of TLR2/TLR9 gene are associated with the progress of cancers. The
present study aimed to investigate the temporal relationship of single nucleotide polymorphisms (SNP) of TLR2/
TLR9 and the risk of hepatocellular carcinoma (HCC).
Methods: In this single center-based case-control study, SNaPshot method was used to genotype sequence
variants of TLR2 and TLR9 in 211 patients with HCC and 232 subjects as controls.
Results: Two synonymous SNPs in the exon of TLR2 were closely associated with risk of HCC. Compared with
those carrying wild-type homozygous genotypes (T/T), risk of HCC decreased significantly in individuals carrying
the heterozygous genotypes (C/T) of the rs3804099 (adjusted odds ratio (OR), 0.493, 95% CI 0.331 - 0.736, P < 0.01)
and rs3804100 (adjusted OR, 0.509, 95% CI 0.342 - 0.759, P < 0.01). There was no significant association found in
two TLR9 SNPs concerning the risk of HCC. The haplotype TT for TLR2 was associated significantly with the
decreased risk of HCC (OR 0.524, 95% CI 0.394 - 0.697, P = 0.000). Inversely, the risk of HCC increased significantly in
patients with the haplotype CC (OR 2.743, 95% CI 1.915 - 3.930, P = 0.000).
Conclusions: These results suggested that TLR2 rs3804099 C/T and rs3804100 C/T polymorphisms were closely
associated with HCC. In addition, the haplotypes composed of these two TLR2 synonymous SNPs have stronger
effects on the susceptibility of HCC.
Background
Toll-like receptors (TLRs) belong to a family of trans-
membrane receptors that play a key role in immune
response against microbial pathogens by recognizing
specific microbial molecular components. After acti-
vated, TLRs initiate a signaling cascade resulting in the
stimulation of innate and adaptive immune responses
targeting the invading pathogen [1].
There are some evidences showing potential associa-
tion between the activation of TLR2/TLR9 and carcino-
genesis. Lipopolysaccharide induces the production of
transforming growth factor-beta and hepatocyte growth
factor mediated by CD14/TLR2 in cultured human
colon cancer cell lines [2]. Listeria monocytogenes could
activate mitogen-activated protein kinases and nuclear
factor-kappaB in tumor cells, resulting in the increased
production of nitric oxide and interleukin-6 and
enhanced proliferation of tumor cells. All of these
effects could be abrogated by silencing expression of
TLR2 [3].
TLR signals exist in hepatitis B, hepatitis C, alcoholic
liver disease, non-alcoholic liver diseases, primary biliary
cirrhosis, primary sclerosing cholangitis, hepatic fibrosis,
ischemic-reperfusion injury and liver allograft rejection
[4]. TLRs can be expressed by various cell types in the
liver. Kupffer cells express TLR2 and TLR9. And hepa-
tocytes and biliary epithelium express TLR2 while stel-
late cells express TLR9 [4]. TLR2 is downregulated in
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cytes in hepatitis-B-antigen-positive patients [5]. In
hepatitis-B-e-antigen-negative patients, TLR2 expression
and tumor necrosis factor-a production is up-regulated
and probably mediated by precore proteins [5]. In vitro,
HBV replication could be inhibited by stimulating IL-1
receptor and TLR2 receptors and subsequently activa-
tion of a signaling cascade in hepatoma cell lines [6]. In
a chemical-induced mouse model developed by Oliva et
al. [7], it was shown that tumorigenesis in liver was
associated with TLR2 activation. The expression of TLR
9 (CpG-specific) was also found in some hepatoma cell
l i n e ss u c ha sH e p G 2 ,H u H 7 ,a n dH e p 3 B .C p GD N Ao f
HBV DNA may contribute to the malignant transforma-
tion of benign liver cells [8]. Cell surface stimulation of
TLR9 promoted cell proliferation and survival in HCC
cell lines [9]. In patients with chronic HBV, TLR9
expression on peripheral blood mononuclear cells was
related to HCC [10]. There is growing evidence showing
the impact of TLR2 and TLR9 genetic polymorphisms
on risk of gallbladder cancer [11], cervical cancer [12],
non-Hodgkin lymphoma [13] and endometrial cancer
[14].
Based on the information above, we hypothesized that
single nucleotide polymorphisms of TLR2 and TLR9
may be related to the occurrence of HCC. To test this
hypothesis, a systematic genetic analysis was performed
in a Chinese population hospital-based HCC case-con-
trol study.
Methods
Study design
The data for total 20 TLR2 and 9 TLR9 SNPs genotyped
in Chinese (CHD) people population from the database
of the International HapMap project http://hapmap.
ncbi.nlm.nih.gov/index.html.zh. Fifteen TLR2 SNPs and
seven TLR9 SNPs were of minor allele frequencies
(MAF) < 5% and were eliminated from subsequent ana-
lysis. The remaining 5 TLR2 SNPs were evaluated: two
synonymous SNPs in the single exon of the gene
(rs3804099, rs3804100) and three SNPs in intron
(rs11938228, rs769632 and rs1898830). Two TLR9 SNPs
were located in intron (rs352139) and exon (rs352140).
Haplotype was analyzed by using a limited number of
TLRs SNPs.
Study samples
We analyzed 211 patients with HCC and 232 non
malignant subjects in this case-control study in Ruijin
Hospital, Shanghai Jiao Tong University School of Medi-
cine. The ethnic backgrounds of subjects were all Chi-
nese. HCC was diagnosed by the elevation of alpha-
fetoprotein (> 400 ng/ml) or by pathological examina-
tion in combination with the results of examination of
iconography including computer tomography or mag-
netic resonance imaging and proved to be without bear-
ing any other cancers. Clinical classification was
according to International Union Against Cancer
(UICC) tumor-node-metastasis (TNM) staging system
[15]. For the severity of liver disease, Child-Pugh score
was evaluated between two groups.
HBV carriers were defined as positive for both hepati-
tis B surface antigen and immunoglobulin G against
hepatitis B core antigen. The treatments for HCC
patients were hepatectomy, liver transplantation, che-
motherapy and transcatheter arterial chemoemboliza-
tion. In order to eliminate the confounding effect of
HBV infection in research of genetic susceptibility to
HCC, controls were randomly selected from the indivi-
duals who attended hepatitis examination in the hospital
during the period of case collection. The selection cri-
teria for the control subjects included no medical his-
tory of any cancer at the time of ascertainment and
frequency matching to the patients on age and gender.
All subjects provided informed consent in this study.
The study protocol was approved by the independent
ethics committee of Ruijin Hospital, Shanghai Jiao Tong
University Medical School.
Genotyping
Genomic DNA was extracted from peripheral blood leu-
kocytes. The genomic regions of interest were amplified
by multiplex polymerase chain reactions (PCRs). The
PCR reactions were performed and all 7 SNPs were gen-
otyped by SNaPshot method according to our previous
protocol [16].
Genotype analysis was performed in a blinded manner
so that staff was unaware of the cases or control status.
For quality control, a 10% masked random sample of cases
and controls was tested repetitively by different investiga-
tors and all the results were completely concordant.
Statistical analysis
Data were expressed as proportions, mean and standard
deviation (SD) or medians (range). All these tests were
performed with the SPSS 13.0 version for Windows. All
reported P values were two sided. Grouped data were
compared by the Mann-Whitney U test.
The Hardy-Weinberg equilibrium (HWE) test using c
2
analysis was done for each SNP among cases and con-
trols. Genotype frequency differences were tested
between HCC patients and control subjects were tested
for each SNP by the c
2 test with 2 degrees of freedom.
Odds ratios (ORs) of HCC for the variant-allele car-
riers (homozygous and heterozygous) versus homozy-
gous wild-type allele carriers were estimated by
unconditional logistic regression and adjusted for sex
and age (< = 55 or > 55).
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wise linkage disequilibrium (LD) (D’) were determined
by using Haploview software http://www.broadinstitute.
org/scientific-community/science/programs/medical-
and-population-genetics/haploview/haploview. The LD
patterns from HapMap CHD population were evaluated
to avoid SNPs in strong LD (r
2 > = 0.8). Haplotype fre-
quency was estimated with the statistical method by
implementing the computer program PHASE. A global
score test was used to assess the difference in haplotype
frequency distributions between cases and controls.
Association between the haplotypes and HCC was per-
formed with the c
2 test.
False-positive report probabilities (FPRPs) for the sig-
nificant results (P < 0.05) were calculated to account for
potential false positives. FPRP is defined as the probabil-
i t yo fn ot r u ea s s o c i a t i o nb e t w e e ng e n e t i cv a r i a n t sa n d
disease given the statistically significant finding. The
values of FPRP were assessed by using the method
described by Wacholder et al. [17]. The FPRP was deter-
mined by: the prior probability of a true association,
observed P value and statistical power. Moderate-high
prior probabilities of 0.10 - 0.25 were assigned and a sig-
nificant finding with a FPRP < 0.50 was considered.
Results
The clinical characteristics of HCC patients and control
subjects were summarized in Table 1 and no significant
differences were observed in age, sex, Child-Pugh score
and HBV carriers between two groups (P > 0.05).
In both HCC patients and control group, the geno-
types of selected polymorphisms of TLR2 and TLR9
were in Hardy-Weinberg equilibrium, with no signifi-
cant c
2 values (P > 0.05) except for rs3804099 and
rs3804100 in control group (P = 0.012). Although
rs3804099 and rs3804100 were deviated from Hardy-
Weinberg equilibrium, we still retained them in the ana-
l y s e sa st h e s eP values were marginal and may be
chance findings and the internal blinded quality-control
specimens did not show evidence of genotyping error.
The two TLR2 polymorphisms were in high LD
(rs1898830 + rs11938228 and rs3804099 + rs3804100,
D’ > 0.9) (see Figure 1).
The genotype frequencies were compared between the
patients and controls for the polymorphisms in TLR2
and TLR9 (see Table 2). Only two TLR2 polymorphisms
(rs3804099 and rs3804100) showed significantly different
distributions between HCC patients and the controls (P
< 0.05) (see Table 2). No different distribution between
HCC patients and the controls was observed in TLR9
SNPs.
Carriers of the C/T of rs3804099 and rs3804100 of
TLR2 had a nominally significant association with
decreased HCC risk (OR 0.493, 95% CI 0.331 - 0.736;
OR 0.509, 95% CI 0.342 - 0.759) by age and sex adjust-
ment (P < 0.01) (see Table 3) compared with T/T car-
riers. No significant association was found in TLR9
polymorphisms with the risk of HCC. Furthermore, we
evaluated the effect of TLR2 and TLR9 SNPs for a-FP
level and UICC pathologic stage in patients with HCC
( s e eT a b l e4 )a n df o u n dt h a tn oS N Ph a da n yi n f l u e n c e
on these two factors.
The haplotype analysis was performed to evaluate the
frequencies of haplotypes based on the two polymorph-
isms within the block 2 of TLR2. The haplotype TT was
associated significantly with the decrease of the risk of
HCC (OR 0.524, 95% CI 0.394 - 0.697, P =0 . 0 0 0 ) .
Inversely, the risk of HCC increased significantly in
patients with the haplotype CC (OR 2.743, 95% CI 1.915
- 3.930, P = 0.000) (see Table 5).
The association for two TLR2 polymorphisms and two
TLR2 haplotypes showed a FPRP below 0.200, which
suggested that these associations are unlikely to repre-
sent a false-positive result (see Table 6).
Discussion
The relationship between TLR2 polymorphisms and the
progresses of tumors have been explored and reported
by some researchers. Boraska Jelavić et al. [18] reported
an association of TLR2 GT microsatelite alleles with 20
and 21 GT repeats with sporadic colorectal cancer
a m o n gC r o a t i a n s .I nt h es t u d yb yS r i v a s t a v ae ta l .[ 1 9 ] ,
del allele carriers of TLR2 (Delta22) polymorphism were
associated with a 1.54-fold increased risk for gallbladder
c a n c e r .I na n o t h e rs t u d yb yP a n d e ye ta l .[ 1 2 ] ,T L R2
gene polymorphisms (-196 to -174 del) showed signifi-
cant association (OR 1.6, 95% CI 1.00-2.51) with cervical
cancer susceptibility. Similarly, it was also confirmed in
the study by Nischalke et al. [20] that the frequency of
Table 1 Main demographic and clinical characteristics of
the studied population
Characteristics HCC
n = 211
Controls
n = 232
P values
Age, year
a 53.87 (18 - 90) 47.07 (22 - 90) 0.309
Male gender, n (%) 178 (84.36%) 187 (80.6%) 0.300
HBV carriers, n (%) 172 (81.52%) 184 (79.3%) 0.559
Child-Pugh score 0.202
A 185 (87.68%) 212 (91.38%)
B 26 (12.32%) 20 (8.62%)
a-FP level
> 400 ng/ml, n (%) 78 (36.97%)
< 400 ng/ml, n (%) 133 (63.03%)
UICC classification
Stage I-II, n (%) 98 (46.45%)
Stage III-IV, n (%) 113 (53.55%)
aMedian (range)
Junjie et al. BMC Cancer 2012, 12:57
http://www.biomedcentral.com/1471-2407/12/57
Page 3 of 8the TLR2 -196 to -174del allele was significantly higher
in cases with HCV-associated HCC than in HCV-
infected patients without HCC. And in carriers of the
TLR2 -196 to -174del allele stimulation of monocytes
resulted in significantly lower TLR2 expression levels
and IL-8 induction than in individuals with the TLR2
-196 to -174ins/ins genotype. The current study was the
first one to show that inherited variation in TLR2 influ-
ences the risk of HCC. We observed the positive asso-
ciation between two SNPs in exon (rs3804099 and
rs3804100) and the risk of HCC. The risk of HCC was
found to be significantly low in individuals carrying the
heterozygous genotypes of these two SNPs by compar-
ing with those carrying wild-type homozygous genotypes
(OR, from 0.331 to 0.759, P < 0.001). Our data sug-
gested that TLR2 gene variation may play an important
protective role in the occurrence of HCC. Though the
observed two-fold decrease in risk is modest, our finding
is intriguing because genes in multiple pathways alter
the risk for HCC, and each individual gene is likely to
contribute only a modest risk.
rs3804099 and rs3804100 of TLR2 are synonymous
SNPs. It has long been assumed that synonymous SNPs
are inconsequential, as they do not lead to a change in
primary polypeptide sequence. However, over the last
decade, it has been confirmed in many studies that
synonymous mutations are implicated in diseases. Sev-
eral mechanisms by which synonymous mutations exert
their impact on gene function are: (1) Perturbations of
mRNA splicing. Ectopic mRNA splicing generated by
synonymous SNPs can bring about distinct phenotypes,
leading to human disease [21]. Synonymous base pair
changes in auxiliary elements within exons (exonic spli-
cing enhancers and exonic splicing silencers) can
directly change the splicing patterns of mRNA tran-
scripts, or they can alter the penetrance of concurring
mutations elsewhere in the gene [22,23]. (2) The stabi-
lity of mRNA. Synonymous SNPs can affect the stability
of mRNA via cis factors which determine mRNA stabi-
lity fall within the 3’-untranslated region of a transcript
[24]. (3) mRNA structure. Synonymous SNPs can modu-
late mRNA structure and have downstream effects on
Figure 1 Linkage disequilibrium plot of TLR2 SNPs in patients with HCC.D ’ corresponding to each SNP pair are expressed as a percentage
and shown within the respective square. Higher D’ is indicated by a brighter red.
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ing. It has been confirmed by some computational and
experimental studies [26,27] that synonymous SNPs
have an influence on protein folding and ultimately pro-
tein function. Which mechanism by these synonymous
SNPs impact should be investigated in future research.
In the present study, LD analysis showed that these
two TLR2 synonymous SNPs were in high LD and
located in one haplotype block. Individuals carrying hap-
lotype TT was significantly associated with the decrease
of the risk of HCC (OR 0.524, 95% CI 0.394 - 0.697, P =
0.000). Inversely, the risk of HCC significantly increased
in patients carrying haplotype CC (OR 2.743, 95% CI
1.915 - 3.930, P =0 . 0 0 0 ) .I nar e c e n ts t u d yb yD i a -
tchenko et al. [28], it was shown that the low pain sensi-
tivity (LPS) haplotype composed of synonymous SNPs
produces much higher levels of the cathechol-O-methyl-
transferase (COMT) enzymatic activity when compared
with the average pain sensitivity (APS) or high pain sen-
sitivity (HPS) haplotypes. The variation in COMT
expression levels among haplotypes was due to the dif-
ferences in protein translation efficiency, which marks
the final manner in which synonymous SNPs can exert
their influence on protein translation and cotranslational
protein folding. Hunt et al. [24] suggested that
Table 2 Genotype distribution of TLR2 and TLR9 SNPs in
HCC patients and controls
SNP Location Genotype HCC Control P values
TLR2 rs7696323 intron C/C 109 125 0.239
C/T 80 93
T/T 22 14
rs1898830 intron G/G 72 80 0.093
A/G 92 118
A/A 47 34
rs11938228 intron A/A 78 84 0.211
A/C 89 113
C/C 44 35
rs3804099 cds-synon C/C 121 100 0.002
C/T 71 117
T/T 19 15
rs3804100 cds-synon C/C 130 111 0.003
C/T 67 110
T/T 14 11
TLR9 rs352140 cds-synon C/C 96 102 0.153
C/T 85 109
T/T 30 21
rs352139 intron A/A 82 101 0.362
G/A 102 110
G/G 27 21
P value was calculated by a c
2-test 3 × 2 contingency table (df = 2)
Table 3 Association between hepatocellular carcinoma and TLR2 and TLR9 SNPs
Gene SNP Genotype Odds Ratio (95% CI) P Value Odds Ratio (95% CI) † P Value
TLR2 rs7696323 C/C 1 1
C/T 1.014 (0.684 - 1.503) 0.946 1.001 (0.673 - 1.489) 0.995
T/T 0.555 (0.271 - 1.137) 0.108 0.560 (0.271 - 1.157) 0.118
rs1898830 A/A 1 1
A/G 0.866 (0.570 - 1.317) 0.502 0.902 (0.591 - 1.378) 0.634
G/G 1.536 (0.891 - 2.647) 0.122 1.531 (0.885 - 2.649) 0.128
rs11938228 C/C 1 1
A/C 0.848 (0.560 - 1.284) 0.437 0.884 (0.582 - 1.344) 0.565
A/A 1.354 (0.789 - 2.324) 0.272 1.340 (0.777 - 2.309) 0.292
rs3804099 T/T 1 1
C/T 0.502 (0.337 - 0.745) 0.001 0.493 (0.331 - 0.736) 0.001
C/C 1.047 (0.506 - 2.166) 0.902 1.048 (0.503 - 2.182) 0.901
rs3804100 T/T 1 1
C/T 0.520 (0.350 - 0.772) 0.001 0.509 (0.342 - 0.759) 0.001
C/C 1.087 (0.474 - 2.490) 0.844 0.844 (0.441 - 2.358) 0.964
TLR9 rs352140 C/C 1 1
C/T 0.829 (0.557 - 1.233) 0.354 0.861 (0.576 - 1.286) 0.464
T/T 1.518 (0.814 - 2.831) 0.19 1.438 (0.767 - 2.695) 0.258
rs352139 G/G 1 1
G/A 1.142 (0.768 - 1.698) 0.512 1.180 (0.790 - 1.761) 0.419
A/A 1.584 (0.835 - 3.004) 0.159 1.521 (0.798 - 2.900) 0.202
† Adjusted for age and sex. P value was calculated by a c
2-test 2 × 2 contingency table (df = 1)
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profound effects on gene function, and in some cases
their effects can be stronger than those of their non-
synonymous counterparts.
Few investigations have been reported about the rela-
tionship between TLR9 polymorphisms and the tumor
susceptivity. In the study by Ashton et al. [14], haplo-
type analysis showed that the combination of the variant
alleles of the two TLR9 polymorphisms, rs5743836 and
rs187084, were protective in endometrial cancer (OR
0.11, 95% CI 0.03-0.44). In a case-control study by Eto-
kebe et al. [29], TLR9 (c.1635A > G) polymorphisms
were not likely to be a risk factor in developing breast
cancer. Although Hold et al. [30] found TLR9 (TLR9-
1237 T/C, rs574383) was associated with the develop-
ment of premalignant gastric lesions in 2006, but their
most recent study showed that this SNP didn’t increase
the risk of gastric cancer itself [31]. Similarly, we didn’t
find any relationship between two TLR9 genetic varia-
tions and the occurrence of HCC.
Recently, Zhang and colleagues [32] conducted a gen-
ome-wide association study by genotyping 440,794 SNPs
in 355 chronic HBV carriers with HCC and 360 chronic
HBV carriers without HCC in Chinese population using
Table 4 Effect of TLR2 and TLR9 SNPs for a-FP level and UICC pathologic stage in patients with hepatocellular
carcinoma
Gene SNP Genotype Odds Ratio (95% CI) † P Value Odds Ratio (95% CI) ‡ P Value
TLR2 rs7696323 C/C 1 1
C/T 0.623 (0.339 - 1.142) 0.126 0.703 (0.393 - 1.257) 0.235
T/T 0.639 (0.241 - 1.693) 0.368 0.402 (0.156 - 1.038) 0.060
rs1898830 A/A 1 1
A/G 0.491 (0.771 - 2.885) 0.235 1.434 (0.740 - 2.635) 0.237
G/G 2.137 (0.994 - 4.597) 0.052 1.304 (0.624 - 2.726) 0.480
rs11938228 C/C 1 1
A/C 1.702 (0.894 - 3.239) 0.106 1.421 (0.771 - 2.616) 0.260
A/A 1.656 (0.764 - 3.587) 0.201 1.458 (0.693 - 3.479) 0.590
rs3804099 T/T 1 1
C/T 1.140 (0.623 - 2.083) 0.671 1.160 (0.644 - 2.088) 0.621
C/C 0.808 (0.287 - 2.276) 0.686 1.308 (0.492 - 3.479) 0.590
rs3804100 T/T 1 1
C/T 1.192 (0.651 - 2.183) 0.569 1.232 (0.681 - 2.230) 0.490
C/C 0.706 (0.210 - 2.377) 0.575 0.940 (0.312 - 2.832) 0.913
TLR9 rs352140 C/C 1 1
C/T 0.928 (0.511 - 1.685) 0.805 0.875 (0.487 - 1.573) 0.655
T/T 0.465 (0.137 - 1.076) 0.054 0.595 (0.260 - 1.360) 0.218
rs352139 G/G 1 1
G/A 1.106 (0.609 - 2.008) 0.741 1.051 (0.587 - 1.884) 0.866
A/A 0.470 (0.171 - 1.292) 0.143 0.691 (0.288 - 1.656) 0.407
† a-FP level: > 400 ng/ml or < = 400 ng/ml
‡ UICC classification: stage I, II or stage III, IV
Table 5 Association of haplotypes in TLR2 with HCC
Haplotype Control Case OR (95% CI) P
Value
Frequency† Frequency†
Block 2
TT 0.585938 0.729748 0.524 (0.394 -
0.697)
0.000
TC 0.067079 0.080679 0.779 (0.457 - 1.329) 0.359
CT 0.086476 0.078309 1.099 (0.664 - 1.818) 0.713
CC 0.260507 0.111264 2.743 (1.915 -
3.930)
0.000
†, proportion of indicated haplotype (%). P value was calculated by a c
2-test 2
× 2 contingency table (df = 1).
Table 6 FPRPs for the selected associations between
genetic polymorphisms and HCC
SNP or
Haplotype
OR
(95% CI)
Observed
P value
Prior probability
0.25 0.1 0.01 0.001
SNP
rs3804099 0.493 z(0.331
- 0.736)
0.001 0.023 0.065 0.434 0.886
rs3804100 0.509 (0.342 -
0.759)
0.001 0.029 0.082 0.497 0.909
Haplotype (Block 2)
TT 0.524 (0.394 -
0.697)
0.000 0.001 0.002 0.018 0.155
CC 2.743 (1.915 -
3.930)
0.000 0.001 0.002 0.018 0.155
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this study, one intronic SNP (rs17401966) in KIF1B on
chromosome 1p36.22 was highly associated with HBV-
related HCC. However, only rs11938228 and rs10759930
of TLR2 and rs1927911 of TLR9 were enrolled in Affy-
metrix Genome-Wide Human SNP Array 5.0 chip and
these three SNPs were not related to HCC. In our
study, only TLR2 rs11938228 was determined and our
result was consistent to them, that TLR2 rs11938228
was not associated with the risk of HCC.
Although SNP rs3804099 and rs3804100 were out of
HWE (P = 0.01 - 0.02), we retained them in the analyses
as these P values were marginal and may be chance
findings and the internal blinded quality-control speci-
mens did not show evidence of genotyping error. These
two SNPs genotyped were deviated HWE in the controls
but not in the cases. The association for these two poly-
morphisms showed a FPRP below 0.200. It suggested
strongly that these associations are unlikely to represent
a false-positive result. Considering these two SNPs
showed any evidence of deviation in cases, it was not
believed that the marginal HWE tests in controls sug-
gest systematic genotyping errors.
Conclusions
TLR2 rs3804099 C/T and rs3804100 C/T polymorph-
isms were associated closely with HCC. In addition, the
haplotypes composed of these two synonymous SNPs
have profound effects on the susceptibility of HCC.
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